# **TIF1**- **Protein Regulates Epithelial-Mesenchymal Transition by Operating as a Small Ubiquitin-like Modifier (SUMO) E3 Ligase for the Transcriptional Regulator SnoN1\***

Received for publication, April 23, 2014, and in revised form, July 23, 2014 Published, JBC Papers in Press, July 24, 2014, DOI 10.1074/jbc.M114.575878

**Yoshiho Ikeuchi**‡§1,2**, Shorafidinkhuja Dadakhujaev**¶1**, Amrita S. Chandhoke**¶ **, Mai Anh Huynh**§ **, Anna Oldenborg**‡ **,**  $\bm{\mathsf{Mikako Ikeuchi^{\$}},$  Lili Deng $^{\P},$  Eric J. Bennett $^{\|\beta}$ , J. Wade Harper $^{\P},$  Azad Bonni $^{\dagger\mathsf{SA}}$ , and Shirin Bonni $^{\dagger\mathsf{SA}}$ 

*From the* ‡ *Department of Anatomy and Neurobiology, Washington University School of Medicine, St. Louis, Missouri 63110, the Departments of* § *Neurobiology and* - *Cell Biology, Harvard Medical School, Boston, Massachusetts 02115, and the* ¶ *Southern Alberta Cancer Research Institute and Department of Biochemistry and Molecular Biology, Cumming School of Medicine, University of Calgary, Calgary, Alberta T2N 4N1, Canada*

**Background:** Epithelial-mesenchymal transition (EMT) plays critical roles in tissue development and cancer biology. Results: TIF1 $\gamma$  promotes sumoylation of SnoN1 and, thereby, regulates EMT.

Conclusion: A novel TIF1 $\gamma$ -SnoN1 sumoylation pathway is crucial for the suppression of EMT.

**Significance:** The identification of the TIF1 $\gamma$ -SnoN1 sumoylation signaling link advances our understanding of EMT.

**Epithelial-mesenchymal transition (EMT) is a fundamental cellular process that contributes to epithelial tissue morphogenesis during normal development and in tumor invasiveness and metastasis. The transcriptional regulator SnoN robustly influences EMT in response to the cytokine TGF, but the mechanisms that regulate the fundamental role of SnoN in TGF-induced EMT are not completely understood. Here we employ** interaction proteomics to uncover the signaling protein TIF1 $\gamma$ **as a specific interactor of SnoN1 but not the closely related isoform SnoN2. A 16-amino acid peptide within a unique region of** SnoN1 mediates the interaction of SnoN1 with TIF1γ. Strik**ingly, although TIF1**- **is thought to act as a ubiquitin E3 ligase, we find that TIF1**- **operates as a small ubiquitin-like modifier (SUMO) E3 ligase that promotes the sumoylation of SnoN1 at** distinct lysine residues. Importantly, TIF1 $\gamma$ -induced sumoyla**tion is required for the ability of SnoN1 to suppress TGF-induced EMT, as assayed by the disruption of the morphogenesis of acini in a physiologically relevant three-dimensional model of normal murine mammary gland (NMuMG) epithelial cells. Collectively, our findings define a novel TIF1**-**-SnoN1 sumoylation**

**pathway that plays a critical role in EMT and has important** implications for our understanding of  $TGF\beta$  signaling and **diverse biological processes in normal development and cancer biology.**

Control of epithelial-mesenchymal transition  $(EMT)^6$  is essential in normal development and homeostasis (1). The cellular morphogenetic events of EMT are comprised of the loss of epithelial cuboidal morphology, loss of cell-cell contact, and the establishment of a fibroblastic mesenchymal shape (2, 3). Attendant with these morphogenetic changes in cells undergoing EMT, markers of epithelial cells such as E-cadherin are down-regulated, and mesenchymal proteins such as N-cadherin are up-regulated (4). EMT of malignant cells in epithelial tumors is thought to portend cancer invasiveness and metastasis (5). Therefore, elucidation of the molecular basis of EMT will advance our understanding of tissue development and cancer.

The cellular and molecular mechanisms that control EMT have been the subject of intense investigation. Much of what we have learned about EMT has come from standard tissue culture studies of epithelial cells. However, three-dimensional models of epithelial cells such as NMuMG mammary epithelial cells provide a more physiologically relevant system in which EMT manifests in the disruption of the normal morphogenesis of tubular acini (6–9).

An essential role for the cytokine  $TGF\beta$  has been established in EMT, which provides the basis for the ability of TGF $\beta$  to promote the progression of epithelial tumors (1–3, 10). Progress has been achieved in our understanding of the signaling mechanisms by which TGF $\beta$  regulates cellular responses,



<sup>\*</sup> This work was supported, in whole or in part, by National Institutes of Health Grants NS041021 (to A. B.) and AG011085 (to J. W. H.). This work was also supported by the Canadian Institutes of Health Research, Alberta Innovates Health Solutions, and Canadian Breast Cancer Foundation-Prairies/ Northwest Territories (to S. B.); by a JSPS postdoctoral fellowship for research abroad (to Y. I.);, and by an Alberta Cancer Foundation graduate studentship (to A. S. D.).<br><sup>1</sup> Both authors contributed equally to this work.

<sup>&</sup>lt;sup>2</sup> Present address: Institute of Industrial Science, The University of Tokyo, Tokyo 153-8505, Japan.<br><sup>3</sup> Present address: Division of Biological Sciences, University of California San

Diego, La Jolla, CA 92093.<br><sup>4</sup> To whom correspondence may be addressed: Dept. of Anatomy and Neurobiology, Washington University School of Medicine, Campus Box 8108, 660 S. Euclid Ave., St. Louis, MO 63110-1093. Tel.: 314-362-3033; E-mail:

sbonni@ucalgary.ca. <sup>5</sup> To whom correspondence may be addressed: Southern Alberta Cancer Research Institute and Dept. of Biochemistry and Molecular Biology, Cumming School of Medicine, University of Calgary, Rm. 377, Heritage Medical Research Bldg., 3330 Hospital Dr., N.W., Calgary, AB T2N 4N1, Canada. Tel.: 403-210-8587; E-mail: sbonni@ucalgary.ca.

<sup>6</sup> The abbreviations used are: EMT, epithelial-mesenchymal transition; SUMO, small ubiquitin-like modifier; TIPtide, TIF1  $\gamma$ -interacting peptide; DIC, differential interference contrast; HCIP, high confidence interacting protein; ANOVA, analysis of variance; NMuMG, normal murine mammary gland; RING, really interesting new gene; TSC, total spectral count.

including EMT. The TGF $\beta$  receptor activates the Smad signaling pathway, which leads to Smad-dependent alterations in gene expression and consequent cellular responses (11). The transcriptional regulator SnoN, which interacts with the transcription factors Smad2, Smad3, and Smad4, suppresses TGFßinduced EMT (12, 13). Although SnoN robustly influences EMT, the mechanisms that regulate the fundamental role of SnoN in EMT are not completely understood.

Posttranslational modifications impact SnoN function in diverse biological settings in proliferating and postmitotic cells. Several ubiquitin ligases, including Cdh1-anaphase-promoting complex (Cdh1-APC), Smurf2, and Arkadia induce the ubiquitination and consequent proteasome-dependent degradation of SnoN (14–17). Ubiquitin-dependent degradation of SnoN influences cell cycle progression in proliferating cells and axon growth in postmitotic neurons (18, 19). SnoN also undergoes sumoylation at the distinct sites lysine 50 and lysine 383, which contributes to the ability of SnoN to regulate transcription (12, 20).

Recent studies suggest that SnoN exerts distinct biological functions in an isoform-specific manner (21). SnoN is the product of the *Sno* (*Ski-related novel*) gene. SnoN1 and SnoN2 represent the two major alternatively spliced isoforms of SnoN that are nearly identical except for a 46-amino acid region that is present in SnoN1 and absent in SnoN2 (22). In the nervous system, SnoN1 and SnoN2 play opposing roles in the control of neuronal migration (21), a biological process with parallels to EMT (23, 24). These studies have raised the fundamental question of whether SnoN might be regulated in an isoform-specific manner and whether such regulation might be of general significance, including in EMT.

In this study, we discovered a novel link between the signaling protein TIF1 $\gamma$  and the transcriptional regulator SnoN1 that plays a critical role in the control of EMT. Using an affinity capture mass spectrometry-based approach, we uncovered the protein TIF1 $\gamma$  as a specific high confidence interactor of SnoN1, but not SnoN2, in cells. In structure-function analyses, we identified a 16-amino acid, TIF1 $\gamma$ -interacting peptide (TIPtide) motif that resides within the unique 46-amino acid region in SnoN1. Strikingly, although TIF1 $\gamma$  reportedly acts as an E3 monoubiquitin ligase for the signaling protein Smad4 (25), we discovered that TIF1 $\gamma$  operates as a SUMO E3 ligase that triggers the sumoylation of SnoN1 at lysines 50 and 383. Importantly, TIF1 $\gamma$ -induced sumoylation of SnoN1 plays a critical role in the ability of SnoN1 to suppress  $TGF\beta$ -induced EMT assayed by the disruption of the morphogenesis of acini in the three-dimensional model of NMuMG mammary epithelial cells. Collectively, our findings define a novel TIF1 $\gamma$ -SnoN1 sumoylation pathway that plays a critical role in EMT. Our study bears significant implications for our understanding of  $TGF\beta$  signaling and diverse biological processes in normal development and cancer biology.

### **EXPERIMENTAL PROCEDURES**

Plasmids and Antibodies-The TIF1 $\gamma$ , SnoN1, and SnoN2 RNAi plasmids were generated to target the sequences GGA-CCAAAGGAAATGTGAAC, AACCAGTAGAGAATTATA-CAGTT, and AAGGCAGAGACAAATTCATCAAT, respec-

tively, as described previously (21, 26, 27). The FLAG-TIF1 $\gamma$ expression plasmid was provided by Dr. Frank J. Rauscher III. The HA- and GFP-TIF1 $\gamma$  expression plasmids were generated by cloning full-length human TIF1 $\gamma$  into pcDNA3 or pEGFP-C1, respectively. The SnoN1/2, SnoN1KdR, and SUMO-SnoN1 expression plasmids have been described previously (20, 21, 28, 29). The mutant TIF1 $\gamma$  and SnoN expression plasmids were generated by site-directed PCR mutagenesis. Rabbit TIF1 $\gamma$ (Bethyl and Santa Cruz Biotechnology), rabbit SnoN (Santa Cruz Biotechnology), rat HA (Roche), mouse FLAG (Sigma), rabbit GFP (Invitrogen), mouse GFP (NeuroMab), rabbit ERK1/2 (Cell Signaling Technology), mouse Cdc27 (Santa Cruz Biotechnology), and rabbit E-cadherin (Cell Signaling Technology) antibodies were used.

*Proteomic Analysis of SnoN Complexes—*293T cells expressing HA-FLAG-SnoN1 or SnoN2 were lysed in lysis buffer (50 mm Tris-HCl (pH 7.5), 150 mm NaCl, 1 mm EDTA, 0.5% Nonidet P-40, and protease inhibitors) and processed for proteomic analysis as described previously (30–32). Briefly, cell lysates were subjected to immunoprecipitation with HA antibody resin (Sigma), and proteins were eluted with HA peptide (Sigma). Eluted proteins were precipitated with trichloroacetic acid and digested with trypsin at 37 °C for 4 h. Digested peptides were desalted with C18 resin (Empore, 3 M), and analyzed with LC-MS/MS using an LTQ linear ion trap mass spectrometer (Thermo Scientific). The resulting spectra were searched using SEQUEST, and the resulting list of identifications was loaded into Comp*PASS* to facilitate a determination of the WD and Z scores (30).

*Analysis of Sumoylation—*Analysis of sumoylation was performed as described previously (28, 29), with modifications. Briefly, 293T cells cotransfected with expression plasmids for  $FLAG-TIF1\gamma$ ,  $HA-SUMO1$ , and  $GFP-SnoN$ , as indicated, were lysed in 150  $\mu$ l of denaturing buffer (150 mm NaCl, 50 mm Tris-HCl (pH 7.5), 1 mM EDTA, 1% Nonidet P-40, 1% SDS, 1 m<sub>M</sub> PMSF, 10 m<sub>M</sub> *N*-ethylmaleimide, 10  $\mu$ g/ml aprotinin, 10  $\mu$ g/ml pepstatin, 10  $\mu$ g/ml leupeptin, 1 mm dithiothreitol, 50 mm NaF, and 1 mm  $Na<sub>3</sub>VO<sub>4</sub>$  and sonicated. The lysate was diluted with 1350  $\mu$ l of lysis buffer (150 mm NaCl, 50 mm Tris-HCl (pH 7.5), 1 mm EDTA, 1% Nonidet P-40, 1 mm PMSF, 10  $\text{mM }$  *N*-ethylmaleimide, 10  $\mu$ g/ml aprotinin, 10  $\mu$ g/ml pepstatin, 10  $\mu$ g/ml leupeptin, 1 mm dithiothreitol, 50 mm NaF, and 1 mm  $Na<sub>3</sub>VO<sub>4</sub>$ ) and subjected to immunoprecipitation with GFP or SnoN antibodies at 4 °C. Immunoprecipitated protein and input samples were subjected to SDS-PAGE, transferred to nitrocellulose membranes, and probed with the indicated antibodies. Analysis of sumoylation was also performed using HepG2 cells or TIF1 $\gamma$  shRNA-expressing HepG2 cells that were prepared with blasticidin selection after transfection with the TIF1  $\gamma$  or control RNAi plasmid together with a blasticidinresistant plasmid using Lipofectamine 2000 (Invitrogen).

*Quantitative RT-PCR—*DNase-treated TRIzol-extracted (Invitrogen) RNA from NMuMG cells was reverse-transcribed using SuperScript II transcriptase (Invitrogen) and oligo(dT)<sub>12–18</sub> (Amersham Biosciences) (12, 26, 33, 34). The cDNAs were subjected to quantitative PCR of the following genes: Zeb1, 5' TCGGAAGACAGAGAATGGAATG3' (forward) and 5'CCTCTTACCTGTGTGCTCATATT3' (reverse);

Zeb2, 5'CTCATTCTGGGTCCTACAGTTC3' (forward) and 5'-GGGAAGAACCCGTCTTGATATT3- (reverse); snail, CCACT-CGGATG TGAAGAGATAC3' (forward) and 5'CCAGACTC-TTGG TGCTTGT3' (reverse); matrix metalloproteinase 9 (MMP9), 5'CTGGAAC TCACACGACATCTT3' (forward) and 5'TCCACCTT GTTCACCTCATTT3' (reverse); plasminogen activator inhibitor 1 (PAI1), 5'TCTCAGAGGTGGAAAGAGC-CAG3' (forward) and 5'TGAAGTAGAGGGCATTCACCA-GC3' (reverse); and, as a housekeeping gene, GAPDH, 5'TCAA-CAGCAACTCCCACTCTTCCA3' (forward) and 5' ACCCTGT-TGCTGTAGCCGTATTCA (reverse), employed as an internal control and using a  $2 \times$  SYBR Green mix (Bio-Rad) and Rotor-Gene thermocycler (Corbett Research). The specificity of the amplification products was confirmed using the melting curve method. Data were analyzed and expressed as described previously (34).

*Three-dimensional NMuMG Cell Acini Formation Assay—* Mouse mammary epithelial (NMuMG) cells were purchased from the ATCC and maintained in growth medium (DMEM containing 10% FBS and 10  $\mu$ g/ml insulin (Invitrogen)) in standard culture dishes in a 5%  $CO<sub>2</sub>$  humidified incubator at 37 °C (12). NMuMG cells were transfected with the indicated plasmids using Lipofectamine LTX with Plus reagent (Invitrogen) 48 or 72 h prior to the following procedure. Three-dimensional cultures of NMuMG cells were prepared in 8-well chamber slides (Millicell EZ Slide, Millipore). 8-well chamber slide wells were precoated with Matrigel (BD Biosciences) cushions, where 75  $\mu$ l of ice-cold 30% growth factor-reduced Matrigel solution (3 mg/ml final concentration) in antibiotic-antimitotic-containing NMuMG growth medium was added to each well. The chamber slides were then transferred to a 5%  $CO<sub>2</sub>$  humidified incubator at 37 °C for 1 h to allow setting of the Matrigel cushions. Next, 75  $\mu$ l of 1.3  $\times$  10<sup>4</sup> cells/ml of NMuMG cells trypsinized and resuspended in a 30% growth factor-reduced Matrigel-containing growth medium was overlaid on top of the Matrigel cushion within each well of the 8-well chamber slides and incubated in a 5%  $CO<sub>2</sub>$  humidified incubator at 37 °C. The next day and every third day, growth medium alone or with 20 pM or 100 pM  $TGF\beta1$  was added until completion of the assay. Differential interference contrast (DIC) images of the live multicellular structures after 10 days in three-dimensional cultures were captured using an inverted microscope with a  $\times$ 20 objective lens (Olympus IX70). The multicellular structures, including acini, were then fixed with 4% paraformaldehyde, permeabilized with 0.5% cold Triton X-100, blocked with 5% BSA in phosphatebuffered saline, and subjected to immunocytochemical analyses using a rabbit E-cadherin antibody (Cell Signaling Technology) as the primary antibody and Cy3-conjugated anti-rabbit IgG (Jackson Lab) as the secondary antibody, and incubated with the DNA dye bisbenzimide (Hoechst 33258) to visualize nuclei (Sigma). Images of multicellular colonies were captured using a fluorescent microscope with a  $\times$ 40 objective lens (Zeiss Axiovert 200 M). For each experiment, exposure times for E-cadherin and Hoechst-derived signals were kept constant. A total of six colonies were assessed for each condition per experiment.

#### **RESULTS**

*Identification of TIF1*- *as an Interaction Partner of SnoN1—* Recent studies suggest that the two isoforms of SnoN, SnoN1 and SnoN2, regulate cellular responses in an isoform-specific manner (21). To determine how SnoN might be regulated isoform-specifically, we performed affinity capture followed by mass spectrometry to identify specific SnoN1- and SnoN2-interacting proteins. We immunopurified SnoN1 or SnoN2 from 293T cells and subjected purified protein complexes to LC-MS/MS analyses to identify associated proteins. We next used the software platform Comparative Proteomics Analysis Software Suite (Comp*PASS*) to compare the SnoN immunoprecipitation/MS dataset against a large number of unrelated parallel immunoprecipitation/MS datasets to distinguish high confidence interacting proteins (HCIPs) from the background (Fig. 1*A*) (30). Comp*PASS* identifies HCIPs on the basis of the WD score, which incorporates the frequency with which they are identified within the stats table, the abundance as represented by total spectral counts when found, and the reproducibility of technical replicates (30). Proteins with WD scores of approximately  $>$ 30 were considered as HCIPs (30). We identified the transcriptional regulatory proteins Smad2, Smad4, and Ski as HCIPs of both SnoN1 and SnoN2 (Fig. 1*A*), validating our proteomics approach because these proteins are known to interact with SnoN (13, 35). Strikingly, we uncovered the protein TIF1  $\gamma$ (also referred to as Trim33) as a robust and specific interactor of SnoN1 but not SnoN2 (Fig. 1*A*). TIF17 was also of particular interest because, similar to SnoN, TIF1 $\gamma$  suppresses TGF $\beta$ -induced EMT (12, 36). These observations raised the fundamental question of whether TIF1 $\gamma$  and SnoN1 might represent components of a novel signaling link that regulates EMT.

We first validated the interaction of TIF1 $\gamma$  with SnoN1 in cells. In coimmunoprecipitation analyses, SnoN1, but not SnoN2, formed a complex with  $TIF1\gamma$  in 293T cells (Fig. 1*B*). Like SnoN2, the SnoN-related protein Ski also failed to interact with TIF1 $\gamma$  (Fig. 1*B*). We also found that endogenous TIF1 $\gamma$ interacted with endogenous SnoN in cells (Fig. 1*C*). Together, these results confirm that TIF1 $\gamma$  and SnoN1 form a complex in cells.

TIF1 $\gamma$  has been suggested to associate with the SnoN1-interacting transcription factors Smad2 and Smad3 (37), raising the question of whether SnoN1 regulates TIF1--Smad2/3 association. To address this question, we examined the coimmunoprecipitation of TIF1 $\gamma$  by Smad2 or Smad3 in the absence or presence of expressed SnoN1. Interestingly, we found that, in the absence of SnoN1, TIF1 $\gamma$  failed to interact with Smad2/3 (Fig. 1*D*). These results suggest that SnoN1 may play a key role in assembling a protein complex containing Smad2 or Smad3 and TIF1 $\gamma$ , with potential functional implications for the TGF $\beta$ -Smad signaling pathway.

*A 16-Amino Acid Region of SnoN1 Interacts with TIF1*-*—*We next performed structure-function analyses to determine the regions of SnoN1 that mediate the TIF1 $\gamma$ -SnoN1 interaction. SnoN1 and SnoN2 are nearly identical, except for a 46-amino acid insert present in SnoN1. The 46-amino acid region of SnoN1 (432– 477) includes amino acid residues conserved across different species (Fig. 2*A*). The finding that SnoN1 selec-





FIGURE 1. **Identification of TIF1** $\gamma$  **as an interaction partner of SnoN1.** A, lysates of 293T cells stably expressing HA-SnoN1 or SnoN2 were immunoprecipitated with HA antibody and subjected to proteomic analysis using LC-MS/MS and Comp*PASS*. *TSC*, total spectral count. *B*, lysates of 293T cells transfected with the GFP-TIF1 $\gamma$  expression plasmid together with an expression plasmid encoding FLAG-SnoN1, FLAG-SnoN2, or FLAG-Ski were immunoprecipitated (*IP*) using the FLAG antibody. *WB*, Western blot. *C*, lysates of HepG2 cells were immunoprecipitated with the TIF1 $\gamma$  antibody or control IgG. Endogenous SnoN formed a complex with endogenous TIF1 $\gamma$  in cells. Treatment of the cells with TGF $\beta$  (2 ng/ml, 1.5 h) did not affect the TIF1 $\gamma$ -SnoN interaction. *D*, lysates of 293T cells transfected with expression plasmids encoding HA-TIF1 $\gamma$  and GFP-SnoN1 or a control vector and FLAG-Smad2, FLAG-Smad3, or a control vector together with a plasmid expressing constitutively active TGF $\beta$ R1 were immunoprecipitated with the FLAG antibody.

tively interacts with TIF1 $\gamma$  suggested that the 46-amino acid region of SnoN1 might play a key role in specifying the TIF1 $\gamma$ -SnoN1 interaction. In deletion analyses of the 46-amino acid region within SnoN1, removal of the N-terminal  $(\Delta 432 - 451)$ or C-terminal  $(\Delta 468 - 477)$  portion of the 46-amino acid region failed to diminish the ability of SnoN1 to form a complex with TIF1 $\gamma$  in cells (Fig. 2*B*). However, deletions that encroached on a 16-amino acid motif (452– 467) profoundly reduced the ability of SnoN1 to interact with  $TIF1\gamma$  in cells (Fig. 2*B*). Alanine scanning mutagenesis within the 16-amino acid TIPtide motif revealed that almost the entire motif was required for robust interaction of SnoN1 with TIF1 $\gamma$  in cells (Fig. 2*C*). In other analyses, the 16-amino acid TIPtide motif within SnoN1 was

sufficient to interact with TIF1 $\gamma$  in cells, albeit less effectively than full-length SnoN1 (Fig. 2*D*). Collectively, these studies suggest that SnoN1 forms a specific complex with TIF1 $\gamma$  in cells.

*TIF1*-*Acts as a Novel SnoN1 SUMO E3 Ligase—*Having identified a specific interaction of TIF1 $\gamma$  with SnoN1, we next determined how TIF1 $\gamma$  might regulate SnoN1. TIF1 $\gamma$  has been reported to form a complex with the SnoN1-interacting transcription factors Smad2 and Smad3 in diverse cell types, including epithelial and embryonic stem cells (13, 37, 38). TIF1 $\gamma$  is classified as a member of the tripartite motif/ring-finger, two-B-boxes (B1 and B2) and a predicted a-helical coiled-coil domain (TRIM/RBCC) family of E3 ubiquitin ligases, containing an N-terminal really interesting new gene (RING) domain, tandem B-box motifs, and C-terminal plant homeodomain (PHD) and bromodomain (BRD) domains (39). Accordingly, TIF1 $\gamma$  appears to promote monoubiquitination of Smad4, which also forms a complex with SnoN1 (13). The TIF1 $\gamma$ -induced ubiquitination of Smad4 inhibits its interaction with Smad2 during embryonic germ layer specification (25, 40). Because SnoN is known to undergo ubiquitination (15–17), we first tested whether TIF1 $\gamma$  might induce ubiquitination of SnoN1. Surprisingly, TIF1 $\gamma$  failed to effectively stimulate ubiquitination of SnoN1 in cells (data not shown).

We reasoned that TIF1 $\gamma$  might induce a distinct lysine-directed modification of SnoN1. Because the TIF1 $\gamma$ -related protein TIF1 $\beta$  operates as a SUMO E3 ligase (41), we asked whether  $TIF1\gamma$  might induce the sumoylation of SnoN1. Remarkably, we found that TIF1 $\gamma$  stimulated the robust covalent modification of SnoN1 with SUMO in cells (Fig. 3*A*). Consistent with the specific interaction of TIF1 $\gamma$  with SnoN1, but not SnoN2, TIF1 $\gamma$  failed to induce the sumoylation of SnoN2 (Fig. 3*A*). Notably, SnoN undergoes sumoylation at lysines 50 and 383 (12, 20). Consistent with a key role for these lysines in TIF1  $\gamma$ -induced sumoylation, TIF1  $\gamma$  failed to induce the sumoylation of a SnoN1 mutant protein in which lysines 50 and 383 were replaced with arginine (SnoN1KdR) (Fig. 3*A*). Because lysines 50 and 383 are present in both SnoN1 and SnoN2, our results suggest that TIF1 $\gamma$  specifically stimulates the sumoylation of SnoN1, but not SnoN2, in cells because of its specific interaction with SnoN1.

To further define the role of TIF1 $\gamma$  in SnoN1 sumoylation, we performed structure-function analyses of TIF1 $\gamma$ . Mutation of two conserved cysteines within the RING domain of TIF1 $\gamma$ (RING CS) disrupted the interaction of TIF1 $\gamma$  with SnoN1 (Fig.  $3B$ ). In contrast, deletion of the middle ( $\Delta$ mid) or the C-terminal region ( $\Delta C$ -term) of TIF1 $\gamma$  did not impair its interaction with SnoN1 (Fig. 3*B*). These results suggest that the RING domain of TIF1 $\gamma$  associates with SnoN1. Consistent with these results, mutation of the RING domain blocked the ability of TIF1- to induce the sumoylation of SnoN1 (Fig. 3*C*). In contrast, deletion of the middle region of TIF1 $\gamma$  had little or no effect on TIF1γ-induced sumoylation of SnoN1 (Fig. 3*C*). Notably, removal of the C-terminal region also blocked the ability of TIF1- to induce the sumoylation of SnoN1 (Fig. 3*C*), suggesting that the C-terminal region is critical for the ability of TIF1 $\gamma$  to promote sumoylation independently of its association with SnoN1. In other experiments, we found that TIF1 $\gamma$  interacted



FIGURE 2. **A 16-amino acid region (TIPtide) mediates SnoN1 interaction with TIF1**-**.** *A*, schematic of SnoN1 and SnoN2, the alternatively spliced isoforms of the *Sno* gene. The dachshund homology domain (*DHD*), SAND domain, Smad2-interacting motif, and coiled-coil domains (*CC*) are indicated. Alignment of the 46-amino acid (*aa*) region from various species indicates conserved amino acids. *B*, lysates of 293T cells transfected with expression plasmids encoding HA-TIF1- and wild-type GFP-SnoN1 or deletion mutants of GFP-SnoN1 were immunoprecipitated (*IP*) with the GFP antibody. *WB*, Western blot. *C*, lysates of 293T cells transfected with expression plasmids encoding HA-TIF1 y and wild-type GFP-SnoN1 or alanine mutants of GFP-SnoN1 were immunoprecipitated with the GFP antibody. *D*, lysates of 293T cells transfected with expression plasmids encoding HA-TIF1<sub>7</sub> and wild-type GFP-SnoN1, GFP-TIPtide, or GFP were immunoprecipitated with the GFP antibody.

with a recombinant form of the SUMO E2 enzyme Ubc9 (Fig. 3D), suggesting that  $TIF1\gamma$  may act as a SUMO E3 ligase. Finally, knockdown of TIF1 $\gamma$  substantially reduced the sumoylation of exogenously expressed SnoN1 or endogenous SnoN in cells (Fig. 3,  $E$  and  $F$ ). Collectively, our data suggest that TIF1 $\gamma$ may act as a SUMO E3 ligase that promotes the sumoylation of SnoN1.

The TIF1 $\gamma$ -SnoN1 Sumoylation Link Controls Epithelial-*Mesenchymal Transition—*The identification of a function for TIF1  $\gamma$  in the sumoylation of SnoN1 led us next to determine the biological implications of the novel TIF1 $\gamma$ -SnoN1 signaling link. TIF1 $\gamma$  and sumoylated SnoN have been implicated in the suppression of TGF $\beta$ -induced EMT in standard two-dimensional cultures of epithelial cells (12, 36). These observations suggested that TIF1 $\gamma$ -induced SnoN1 sumoylation might play a critical role in the regulation of EMT. To address this question, we employed three-dimensional cultures of non-transformed NMuMG mammary epithelial cells in these analyses because these cultures provide a more physiologically relevant system for the study of biological processes, including EMT  $(6-8)$ . Subjecting NMuMG cells in which SnoN1 shRNAs or SnoN2 shRNAs were expressed to immunoblotting with the SnoN antibody confirmed that NMuMG cells expressed the two isoforms SnoN1 and SnoN2 (Fig. 4*A*) (21). In the three-dimen-





FIGURE 3. **TIF1**  $\gamma$  **acts as a novel SnoN1 SUMO E3 ligase.** A, lysates of 293T cells transfected with the FLAG-TIF1  $\gamma$  expression plasmid or control vector together with the HA-SUMO1 and GFP-SnoN1, SnoN2, or SnoN1KdR expression plasmid were immunoprecipitated (*IP*) with the GFP antibody. *WB*, Western blot. *B*, lysates of 293T cells transfected with expression plasmids encoding GFP-SnoN1 and wild-type FLAG-TIF1 $\gamma$  or deletion mutants of FLAG-TIF1 $\gamma$  were immunoprecipitated with the FLAG antibody. *Vec*, vector. C, lysates of 293T cells transfected with the FLAG-TIF1<sub>7</sub> expression plasmid, deletion mutants of FLAG-TIF1<sub>7</sub>, or control vector together with the HA-SUMO1 expression plasmid and GFP-SnoN1 were sonicated and immunoprecipitated with the GFP antibody. *D*, lysates of 293T cells transfected with FLAG-TIF1 y were subjected to a pulldown assay with GST-UBC9 or GST and immunoblotted with FLAG antibody or stained with Ponceau S dye. *E*, lysates of HepG2 cells stably transfected with an RNAi plasmid expressing shRNAs targeting TIF1  $\gamma$  or the control U6 plasmid and transiently transfected with the GFP-SnoN1 or GFP-SnoN1KdR expression plasmid together with the HA-SUMO1 expression plasmid or a control vector were sonicated and immunoprecipitated with the GFP antibody. F, lysates of HepG2 cells stably expressing shRNAs targeting TIF1 $\gamma$  or control cells were sonicated and immunoprecipitated with the IgG control or SnoN antibody, followed by immunoblotting with the SnoN and TIF1- antibodies (*bottom panel*). Lysates (*top*  $\it panel$ ) were immunoblotted with the TIF1  $\gamma$  or Cdc27 antibody, the latter serving as a loading control.



were immunoblotted with the SnoN antibody. *Ctrl*, control. \* a non-specific immunoreactive band. *B*, representative DIC images (*left panel*) and quantification of acini or filled colony morphology (right panel, mean ± S.E., *n* = 3) of NMuMG cells left untreated or incubated with 100 pM TGF β for 10 days. TGF β reduced the proportion of acini with hollow centers (ANOVA, *p* < 0.001). The TGF*β*-specific receptor kinase inhibitor SB-431542 (*KI*) reversed the effect of TGF*β*. *C*, three-dimensional NMuMG cultures as in *B* were subjected to immunocytochemistry using the E-cadherin (*E-cad*, *red*) antibody and Hoechst 33258 (*blue*). *B* and *C*,*scale bar* 50 m.



sional cultures, NMuMG cells underwent cell proliferation and cell-cell attachment and organized into acini with hollow centers (Fig. 4*B*), reflecting the apical-basal polarity nature of these structures and, thus, phenocopying the *in vivo* acinar nature of glandular epithelial tissue  $(6-8)$ . Supporting this idea, immunofluorescence analyses of three-dimensional NMuMG cell cultures showed basolateral localization of the epithelial marker E-cadherin (Fig. 4*C*). Exposure of the three-dimensional NMuMG cell culture to  $TGF\beta$  induced acinar lumen filling, outward protrusions at the basal surface, and deformation of the acinar structures (Fig. 4, *B* and *C*). The alterations in acinar morphology were accompanied by the down-regulation and loss of the basolateral localization of E-cadherin (Fig. 4*C*). Inhibition of the  $TGF\beta$ -type I receptor kinase rescued normal acini morphology and E-cadherin abundance and localization in TGF $\beta$ -treated NMuMG cells (Fig. 4,  $\beta$  and  $\beta$ ), suggesting that the canonical TGF $\beta$  pathway plays a critical role in the ability of  $TGF\beta$  to induce dysregulation of acinar morphology and associated loss of E-cadherin levels in NMuMG cells. Collectively, these findings show that NMuMG cells form organized acini in three-dimensional cultures and that  $TGF\beta$  triggers stereotypic alterations in acinar morphogenesis reflecting EMT.

We compared the effect of wild-type SnoN1, a sumoylation gain-of-function SnoN1 in which SUMO is fused to SnoN1 (SUMO-SnoN1), or the SnoN1KdR loss of sumoylation mutant on the ability of TGF $\beta$  to disrupt the morphogenesis of acini in three-dimensional cultures of NMuMG cells. We found that SnoN1 and SUMO-SnoN1 suppressed the ability of TGF $\beta$  to induce lumen filling and disorganization of NMuMG cell acini (Fig. 5*A*). In contrast, expression of SnoN1KdR enhanced lumen filling of NMuMG acini (Fig. 5*A*). Immunocytochemical analyses showed that SnoN1 and SUMO-SnoN1 blocked, whereas SnoN1KdR promoted, the ability of TGF $\beta$  to downregulate and disrupt the basolateral localization of E-cadherin (Fig. 5*B*). These data suggest that sumoylation of SnoN1 suppresses the ability of  $TGF\beta$  to induce EMT in NMuMG cell acini.

We next asked whether TIF1 $\gamma$  regulates TGF $\beta$ -induced EMT in three-dimensional cultures of NMuMG cells in a SnoN1 sumoylation-dependent manner. Like SnoN1 and SUMO-SnoN1, TIF1 $\gamma$  antagonized the ability of TGF $\beta$  to induce the lumen filling and loss and mislocalization of E-cadherin in NMuMG cell acini (Fig. 5, *C* and *D*). Importantly, the TIF1 $\gamma$  RING CS mutant, which failed to interact with SnoN1 and induce its sumoylation (Fig. 3, *B* and *C*), failed to suppress and, instead, promoted the ability of TGF $\beta$  to disrupt acinar morphogenesis and to down-regulate E-cadherin (Fig. 5, *C* and D). Likewise, the TIF1 $\gamma$   $\Delta C$ -term mutant, which failed to induce SnoN1 sumoylation (Fig. 3*C*), failed to suppress and, instead, promoted the ability of TGF $\beta$  to disrupt acinar morphogenesis and to down-regulate E-cadherin in three-dimensional cultures of NMuMG cells (Fig. 5, *C* and *D*). Therefore, the phenotypes induced by the expression of the RING CS or  $\Delta C$ -term TIF1 $\gamma$  mutant mimicked the phenotypes induced by SnoN1KdR in NMuMG cell acini. Interestingly, the RING CS and  $\Delta {\rm C}$ -term TIF1 $\gamma$  mutants and SnoN1KdR induced EMTlike alterations in NMuMG cell acini even in the absence of exogenous TGF $\beta$  (Fig. 5), suggesting that these mutants interfere dominantly with the function of endogenous TIF1 $\gamma$ . Consistent with these results, knockdown of endogenous TIF1 $\gamma$  in NMuMG cells triggered lumen filling and loss of E-cadherin in NMuMG cell acini in the absence of TGFβ (Figs. 6, *A* and *B*). These results suggest that endogenous TIF1 $\gamma$  regulates EMT in mammary cell acini.

We also performed epistasis analyses to determine the relationship of TIF1 $\gamma$  and SnoN1 sumoylation in the control of EMT in mammary cell acini. Expression of SUMO-SnoN1 suppressed the ability of TIF1 $\gamma$  knockdown to induce the phenotype of lumen filling and loss of E-cadherin in NMuMG cell acini in the presence or absence of  $TGF\beta$  (Fig. 6,  $A$  and  $B$ ). In other experiments, we found that expression of the sumoylation-deficient SnoN1KdR mutant or knockdown of SnoN1 suppressed the ability of TIF1 $\gamma$  to inhibit TGF $\beta$ -induced acini filling and loss of E-cadherin in the three-dimensional cultures of NMuMG cells (Figs. 6, *C* and *D*, and 7, *A* and *B*). These data suggest that TIF1 $\gamma$  acts via sumoylation of SnoN1 to suppress EMT and the consequent disruption of acinar morphogenesis.

 $TGF\beta$  induces the expression of a number of transcription factors, including Zeb1, Zeb2, and snail, which, in turn, lead to repression of E-cadherin, a hallmark of EMT (1, 42). To gain further insight into the potential mechanism by which the TIF1 $\gamma$ -SnoN sumoylation axis controls EMT, we characterized the role of the TIF1 $\gamma$ -SnoN1 sumoylation pathway in TGF $\beta$ up-regulation of Zeb1, Zeb2, and snail. In quantitative RT-PCR analyses, expression of the SUMO gain-of-function SnoN1, SUMO-SnoN1, or TIF1 $\gamma$  significantly suppressed the expression of Zeb1, Zeb2, and snail in  $TGF\beta$ -treated NMuMG cells (Fig. 8, *A* and *B*). MMP9 and PAI-1 are extracellular genes that are induced by TGF $\beta$  and contribute to EMT (43, 44). Just as in the case of TGF $\beta$ -regulated transcription factors, SUMO-SnoN1 and TIF1 $\gamma$  suppressed the expression of MMP9 and PAI1 in TGFß-treated NMuMG cells (Fig. 8, C and D). Collectively, our data define TIF1y-SnoN1 sumoylation as a novel signaling link in the control of TGF $\beta$ -regulation of epithelial tissue morphogenesis.

## **DISCUSSION**

In this study, we discovered a novel TIF1 $\gamma$ -SnoN1 sumoylation signaling mechanism that regulates EMT. Utilizing the Comp*PASS* interaction proteomics platform (30), we identified the signaling protein TIF1  $\gamma$  as a novel and specific interactor of the transcriptional regulator protein SnoN1 but not the closely related isoform SnoN2. Structure-function analyses further revealed that a 16-amino acid peptide motif within a unique region of SnoN1 mediates its interaction with TIF1  $\gamma$ . Strikingly, whereas TIF1 $\gamma$  is thought to stimulate the ubiquitination of the transcription factor Smad4, we found that TIF1  $\gamma$  stimulates the sumoylation of SnoN1. Importantly,  $TIF1\gamma$ -induced SnoN1 sumoylation suppresses EMT, as assayed by disruption of the morphogenesis of acini in three-dimensional cultures of NMuMG mammary epithelial cells. Collectively, our findings define an intimate link between TIF1  $\gamma$  and SnoN1 that controls epithelial tissue morphogenesis.

The identification of a TIF1 $\gamma$ -SnoN1 sumoylation signaling link advances our understanding of the mechanisms that con-





FIGURE 5. **TIF1**- **and SnoN1 control epithelial morphogenesis.** *A*, representative DIC images (*left panel*) and quantification of acini or filled colony morphology (right panel, mean  $\pm$  S.E.,  $n = 3$  or 4) of NMuMG cells transfected with vector control, wild-type SnoN1, SnoN1KdR, or SUMO-SnoN1-expressing plasmids that were left untreated or incubated with 20 pm or 100 pm TGF $\beta$  for 10 days. Wild-type SnoN1 and SUMO-SnoN1 significantly suppressed the ability of TGF $\beta$ to reduce the proportion of hollow acini ( $p < 0.05$ ). SnoN1KdR decreased the proportion of hollow acini even in untreated three-dimensional cultures ( $p <$ 0.001). *B*, three-dimensional NMuMG cultures as in *A* were analyzed as in Fig. 4*C*. *E-cad*, E-cadherin. *C*, representative DIC images (*left panel*) and quantification of colony morphology (right panel) of NMuMG cells transfected with expression plasmids encoding GFP and wild-type FLAG-TIF1 $\gamma$ , FLAG-TIF1 $\gamma$  RING CS, or FLAG-TIF1 y  $\Delta C$ -term that were left untreated or incubated with 20 pm or 100 pm TGFB for 10 days. Wild-type TIF1 y significantly suppressed the ability of TGFB to reduce the proportion of hollow acini (ANOVA,  $\rho$  < 0.001). Both TIF1  $\gamma$  mutants decreased the proportion of acini with hollow centers even in the absence of TGF $\beta$  addition (ANOVA,  $p < 0.001$ ). *D*, three-dimensional NMuMG cultures as in *C* were analyzed as in Fig. 4*C*. *A*–*C*, *scale bar* = 50  $\mu$ m.





FIGURE 6. **TIF1**- **acts via SnoN1 sumoylation to control epithelial morphogenesis.** *A*, representative DIC images (*left panel*) and quantification of colony morphology (right panel, mean  $\pm$  S.E.,  $n=3$  or 4) of NMuMG cells transfected with vector control, the RNAi plasmid encoding TIF1  $\gamma$  shRNAs, SUMO-SnoN1 expression plasmid, or the RNAi plasmid encoding TIF1 y shRNAs together with the SUMO-SnoN1 expression plasmid that were left untreated or incubated with 20 pm or 100 pm TGFβ for 10 days. TIF1 y RNAi decreased the proportion of acini with hollow centers even in the absence of TGFβ addition (ANOVA,  $p$   $<$ 0.01). SUMO-SnoN1 reversed the ability of TIF1 $\gamma$  RNAi to reduce hollow acini under all three conditions (ANOVA,  $p <$  0.05). *B*, three-dimensional NMuMG cultures as in *A* were analyzed as in Fig. 4*C*. *E-cad*, E-cadherin. *C*, representative DIC images (*left panel*) and quantification of colony morphology (*right panel*) of NMuMG cells transfected with the vector control, expression plasmid encoding wild type TIF1 $\gamma$ , SnoN1KdR, or TIF1 $\gamma$  together with SnoN1KdR that were left untreated or incubated with 20 pm or 100 pm TGF $\beta$  for 10 days. SnoN1KdR suppressed the ability of wild-type TIF1 $\gamma$  to maintain the proportion of hollow acini in the absence and presence of 20 pm TGF $\beta$  (ANOVA,  $p < 0.05$ ). *D*, three-dimensional NMuMG cultures as in *C* were analyzed as in Fig. 4*C*.  $A$ –*C*, *scale bar* = 50  $\mu$ m.





FIGURE 7. SnoN1 operates downstream of TIF1  $\gamma$  to control epithelial morphogenesis. A, representative DIC images (l*eft panel*) and quantification of acini or filled colony morphology (*right panel*, mean ± S.E., *n* = 6) of NMuMG cells transfected with vector control, TIF1γexpression plasmid, the RNAi plasmid encoding SnoN1 shRNA, or TIF1 y expression plasmid together with the SnoN1 RNAi plasmid that were left untreated or incubated with 20 pm or 100 pm TGF $\beta$ for 10 days. TIF1 $\gamma$  did not reverse the ability of SnoN RNAi to reduce hollow acini (ANOVA,  $p < 0.001$ ). B, three-dimensional NMuMG cultures as in *A* were analyzed as in Fig. 4*C*. *E-cad*, E-cadherin. *B*, *scale bar* = 50  $\mu$ m.

trol epithelial tissue morphogenesis with implications for normal development and cancer biology.  $TGF\beta$ -induced EMT plays a critical role in tissue morphogenesis in diverse systems during normal embryogenesis as well as during cancer invasiveness and metastasis  $(1-3)$ . The finding that TIF1 $\gamma$ -induced sumoylation of SnoN1 suppresses  $TGF\beta$ -induced EMT suggests that it will be interesting to determine whether the novel TIF1  $\gamma$ -induced SnoN1 sumoylation link might regulate normal epithelial tissue morphogenesis and the invasiveness and metastatic potential of epithelial tumors.

Our data suggest that the canonical Smad2/3 pathway contributes significantly to the ability of  $TGF\beta$  to induce EMT, as evidenced by a complete reversal of  $TGF\beta$ -induced acinar dysregulation by specific inhibition of the  $TGF\beta$  type I receptor kinase. Other reports have suggested that  $TGF\beta$  activation of other signaling proteins, such as Smad1/5/8 or ERK, may also contribute to EMT (42, 45). We found that TGF $\beta$  modestly and only transiently induced Smad1 phosphorylation and did not induce ERK phosphorylation in NMuMG cells (data not shown). Therefore, our data suggest that the TIF1 $\gamma$ -SnoN1 sumoylation axis suppresses EMT by disruption of the canonical TGF $\beta$  pathway.

In addition to TIF1 $\gamma$ , the SUMO E3 ligase PIAS1 acts as a SUMO E3 ligase for SnoN that regulates EMT (12). Therefore, TIF1 $\gamma$  and PIAS1 may cooperate in cells to stimulate the sumoylation of SnoN and, thereby, regulate EMT. In future studies, it will be important to determine whether PIAS1 stimulates sumoylation of both SnoN1 and SnoN2. In that scenario,

it will be interesting to determine whether TIF1 $\gamma$  and PIAS1 have differential biological effects of SnoN.

The identification of a novel interaction between TIF1  $\gamma$  and SnoN1 also bears significant implications for our understanding of TGFß-regulated signaling pathways. Intriguingly, TIF1 $\gamma$ is thought to regulate hematopoietic cell differentiation through formation of a complex with the SnoN1-interacting transcription factor Smad2/3 (37). TIF1  $\gamma$  also appears to induce the ubiquitination of Smad4, another SnoN1-interacting transcription factor (25, 37, 40). In our analyses, we identified a specific 16-amino acid peptide (TIPtide) within a unique region of SnoN1 that mediates the interaction of SnoN1 with TIF1 $\gamma$ . Notably, a distinct domain within the N-terminal region and the sp100, AIRS-1, NucP41/75, DEAF-1 (SAND) domain of SnoN mediates its interaction with the transcription factors Smad2/3 and Smad4, respectively (46). Consistent with the possibility that SnoN1 might mediate the interaction of TIF1 $\gamma$ and Smad proteins, in our experiments, TIF1  $\gamma$  failed to interact with Smad proteins in cells in the absence of SnoN1. Therefore, SnoN1 might facilitate the biological consequences attributed to TIF1 $\gamma$ -Smad interactions, such as the control of hematopoietic cell differentiation and germ layer specification during embryogenesis. Our findings may shed further light on the role of TIF1 $\gamma$  in regulating TGF $\beta$  signaling and biological responses.

Our findings also have implications for our understanding of SnoN1 functions beyond the control of EMT in epithelial tissues. In the nervous system, SnoN1 forms, isoform-specifically, a transcriptional repressor complex with the transcription fac-



FIGURE 8. **TIF1**-**-SnoN sumoylation suppresses TGF-induced gene expression in EMT.** *A*, quantitative RT-PCR analysis of mRNA extracted from NMuMG cells transfected with a vector control or a SUMO-SnoN1 expressing plasmid that were left untreated or incubated with 100 pm TGF $\beta$  for 24 h to measure the abundance of the mRNA of Zeb1, Zeb2, snail, and GAPDH, with the latter serving as the internal control for normalization. The mean mRNA abundance is presented relative to the expression of the plus TGF $\beta$  control, together with the mean  $\pm$  S.E. from four independent experiments. SUMO-SnoN1 significantly suppressed the expression of Zeb1, Zeb2, and snail in TGF $\beta$ -treated NMuMG cells (ANOVA,  $p < 0.001$ ). *B*, quantitative RT-PCR analysis of mRNA from NMuMG cells transfected with a vector control or a plasmid encoding FLAG-TIF1  $\gamma$  that were analyzed as described in A. TIF1  $\gamma$  significantly suppressed the expression of Zeb1, Zeb2, and snail in TGF $\beta$ -treated NMuMG cells (ANOVA,  $p < 0.001$ ). *C*, quantitative RT-PCR analysis of MMP9 and PAI-1 as described in A. SUMO-SnoN1 suppressed the expression of MMP9 and PAI-1 in TGF $\beta$ -treated NMuMG cells (ANOVA,  $p < 0.05$ ). *D*, quantitative RT-PCR analysis of MMP9 and PAI-1 as described in B. TIF1 $\gamma$  suppressed the expression of MMP9 and PAI-1 in TGF $\beta$ -treated NMuMG cells (ANOVA,  $p < 0.001$ ).

tor FOXO1 and, thereby, regulates neuronal branching and migration in the developing mammalian brain (21). In addition, SnoN1 and SnoN2 promote axon growth in the developing brain (14, 18, 19). In future studies, it will be interesting to determine whether and how TIF1 $\gamma$ -induced sumoylation of SnoN1 might impact the key developmental events of axon growth, branching, and neuronal migration in the brain.

In summary, we identified a novel function for the signaling protein TIF1 $\gamma$  as a SnoN1 SUMO E3 ligase. The TIF1 $\gamma$ -SnoN1 sumoylation link plays a critical role in epithelial tissue morphogenesis. In addition to advancing our understanding of normal development, our findings may suggest potential new druggable targets for the treatment of malignant epithelial tumors.

*Acknowledgments—We thank the members of the Bonni laboratory for helpful discussions and critical reading of the manuscript and Frank J. Rauscher III for the FLAG-TIF1*- *plasmid.*

#### **REFERENCES**

- 1. Thiery, J. P., Acloque, H., Huang, R. Y., and Nieto, M. A. (2009) Epithelialmesenchymal transitions in development and disease. *Cell* **139,** 871–890
- 2. Jakowlew, S. B. (2006) Transforming growth factor- $\beta$  in cancer and metastasis. *Cancer Metastasis Rev.* **25,** 435–457
- 3. Kang, Y., and Massagué, J. (2004) Epithelial-mesenchymal transitions:

## *A TIF1*-*-SnoN1 Sumoylation Pathway Regulates EMT*

twist in development and metastasis. *Cell* **118,** 277–279

- 4. Thiery, J. P., and Sleeman, J. P. (2006) Complex networks orchestrate epithelial-mesenchymal transitions. *Nat. Rev. Mol. Cell Biol.* **7,** 131–142
- 5. Thiery, J. P. (2002) Epithelial-mesenchymal transitions in tumour progression. *Nat. Rev. Cancer* **2,** 442–454
- 6. Shaw, K. R., Wrobel, C. N., and Brugge, J. S. (2004) Use of three-dimensional basement membrane cultures to model oncogene-induced changes in mammary epithelial morphogenesis. *J. Mammary Gland Biol. Neoplasia* **9,** 297–310
- 7. Godde, N. J., Galea, R. C., Elsum, I. A., and Humbert, P. O. (2010) Cell polarity in motion: redefining mammary tissue organization through EMT and cell polarity transitions. *J. Mammary Gland Biol. Neoplasia* **15,** 149–168
- 8. Debnath, J., and Brugge, J. S. (2005) Modelling glandular epithelial cancers in three-dimensional cultures. *Nat. Rev. Cancer* **5,** 675–688
- 9. Moreno-Bueno, G., Peinado, H., Molina, P., Olmeda, D., Cubillo, E., Santos, V., Palacios, J., Portillo, F., and Cano, A. (2009) The morphological and molecular features of the epithelial-to-mesenchymal transition. *Nat. Protoc.* **4,** 1591–1613
- 10. Zavadil, J., and Böttinger, E. P. (2005) TGF- $\beta$  and epithelial-to-mesenchymal transitions. *Oncogene* **24,** 5764–5774
- 11. Shi, Y., and Massagué, J. (2003) Mechanisms of TGF- $\beta$  signaling from cell membrane to the nucleus. *Cell* **113,** 685–700
- 12. Netherton, S. J., and Bonni, S. (2010) Suppression of TGFB-induced epithelial-mesenchymal transition like phenotype by a PIAS1 regulated sumoylation pathway in NMuMG epithelial cells. *PLoS ONE* **5,** e13971
- 13. Stroschein, S. L., Wang, W., Zhou, S., Zhou, Q., and Luo, K. (1999) Negative feedback regulation of TGF- $\beta$  signaling by the SnoN oncoprotein. *Science* **286,** 771–774
- 14. Stegmüller, J., Huynh, M. A., Yuan, Z., Konishi, Y., and Bonni, A. (2008) TGFB-Smad2 signaling regulates the Cdh1-APC/SnoN pathway of axonal morphogenesis. *J. Neurosci.* **28,** 1961–1969
- 15. Bonni, S., Wang, H. R., Causing, C. G., Kavsak, P., Stroschein, S. L., Luo, K., and Wrana, J. L. (2001) TGF- $\beta$  induces assembly of a Smad2-Smurf2 ubiquitin ligase complex that targets SnoN for degradation. *Nat. Cell Biol.* **3,** 587–595
- 16. Levy, L., Howell, M., Das, D., Harkin, S., Episkopou, V., and Hill, C. S. (2007) Arkadia activates Smad3/Smad4-dependent transcription by triggering signal-induced SnoN degradation. *Mol. Cell Biol.* **27,** 6068–6083
- 17. Nagano, Y., Mavrakis, K. J., Lee, K. L., Fujii, T., Koinuma, D., Sase, H., Yuki, K., Isogaya, K., Saitoh, M., Imamura, T., Episkopou, V., Miyazono, K., and Miyazawa, K. (2007) Arkadia induces degradation of SnoN and c-Ski to enhance transforming growth factor- $\beta$  signaling. *J. Biol. Chem.* 282, 20492–20501
- 18. Ikeuchi, Y., Stegmüller, J., Netherton, S., Huynh, M. A., Masu, M., Frank, D., Bonni, S., and Bonni, A. (2009) A SnoN-Ccd1 pathway promotes axonal morphogenesis in the mammalian brain. *J. Neurosci.* **29,** 4312–4321
- 19. Stegmüller, J., Konishi, Y., Huynh, M. A., Yuan, Z., Dibacco, S., and Bonni, A. (2006) Cell-intrinsic regulation of axonal morphogenesis by the Cdh1- APC target SnoN. *Neuron* **50,** 389–400
- 20. Hsu, Y. H., Sarker, K. P., Pot, I., Chan, A., Netherton, S. J., and Bonni, S. (2006) Sumoylated SnoN represses transcription in a promoter-specific manner. *J. Biol. Chem.* **281,** 33008–33018
- 21. Huynh, M. A., Ikeuchi, Y., Netherton, S., de la Torre-Ubieta, L., Kanadia, R., Stegmüller, J., Cepko, C., Bonni, S., and Bonni, A. (2011) An isoformspecific SnoN1-FOXO1 repressor complex controls neuronal morphogenesis and positioning in the mammalian brain. *Neuron* **69,** 930–944
- 22. Pearson-White, S., and Crittenden, R. (1997) Proto-oncogene Sno expression, alternative isoforms and immediate early serum response. *Nucleic Acids Res.* **25,** 2930–2937
- 23. Itoh, Y., Moriyama, Y., Hasegawa, T., Endo, T. A., Toyoda, T., and Gotoh, Y. (2013) Scratch regulates neuronal migration onset via an epithelialmesenchymal transition-like mechanism. *Nat. Neurosci.* **16,** 416–425
- 24. Rogers, C. D., Saxena, A., and Bronner, M. E. (2013) Sip1 mediates an E-cadherin-to-N-cadherin switch during cranial neural crest EMT. *J. Cell Biol.* **203,** 835–847
- 25. Dupont, S., Mamidi, A., Cordenonsi, M., Montagner, M., Zacchigna, L., Adorno, M., Martello, G., Stinchfield, M. J., Soligo, S., Morsut, L., Inui, M.,



Moro, S., Modena, N., Argenton, F., Newfeld, S. J., and Piccolo, S. (2009) FAM/USP9x, a deubiquitinating enzyme essential for TGF $\beta$  signaling, controls Smad4 monoubiquitination. *Cell* **136,** 123–135

- 26. Sarker, K. P., Wilson, S. M., and Bonni, S. (2005) SnoN is a cell typespecific mediator of transforming growth factor- $\beta$  responses. *J. Biol. Chem.* **280,** 13037–13046
- 27. Gaudilliere, B., Shi, Y., and Bonni, A. (2002) RNA interference reveals a requirement for myocyte enhancer factor 2A in activity-dependent neuronal survival. *J. Biol. Chem.* **277,** 46442–46446
- 28. Shalizi, A., Bilimoria, P. M., Stegmüller, J., Gaudillière, B., Yang, Y., Shuai, K., and Bonni, A. (2007) PIASx is a MEF2 SUMO E3 ligase that promotes postsynaptic dendritic morphogenesis. *J. Neurosci.* **27,** 10037–10046
- 29. Shalizi, A., Gaudillière, B., Yuan, Z., Stegmüller, J., Shirogane, T., Ge, Q., Tan, Y., Schulman, B., Harper, J. W., and Bonni, A. (2006) A calciumregulated MEF2 sumoylation switch controls postsynaptic differentiation. *Science* **311,** 1012–1017
- 30. Sowa, M. E., Bennett, E. J., Gygi, S. P., and Harper, J. W. (2009) Defining the human deubiquitinating enzyme interaction landscape. *Cell* **138,** 389–403
- 31. Litterman, N., Ikeuchi, Y., Gallardo, G., O'Connell, B. C., Sowa, M. E., Gygi, S. P., Harper, J. W., and Bonni, A. (2011) An OBSL1-Cul7Fbxw8 ubiquitin ligase signaling mechanism regulates Golgi morphology and dendrite patterning. *PLoS Biol.* **9,** e1001060
- 32. Zhang, C., Mejia, L. A., Huang, J., Valnegri, P., Bennett, E. J., Anckar, J., Jahani-Asl, A., Gallardo, G., Ikeuchi, Y., Yamada, T., Rudnicki, M., Harper, J. W., and Bonni, A. (2013) The X-linked intellectual disability protein PHF6 associates with the PAF1 complex and regulates neuronal migration in the mammalian brain. *Neuron* **78,** 986–993
- 33. Eapen, S. A., Netherton, S. J., Sarker, K. P., Deng, L., Chan, A., Riabowol, K., and Bonni, S. (2012) Identification of a novel function for the chromatin remodeling protein ING2 in muscle differentiation. *PLoS ONE* **7,** e40684
- 34. Pot, I., Patel, S., Deng, L., Chandhoke, A. S., Zhang, C., Bonni, A., and Bonni, S. (2013) Identification of a novel link between the protein kinase NDR1 and TGF signaling in epithelial cells. *PLoS ONE* **8,** e67178
- 35. Cohen, S. B., Zheng, G., Heyman, H. C., and Stavnezer, E. (1999) Heterodimers of the SnoN and Ski oncoproteins form preferentially over ho-

modimers and are more potent transforming agents. *Nucleic Acids Res.* **27,** 1006–1014

- 36. Hesling, C., Fattet, L., Teyre, G., Jury, D., Gonzalo, P., Lopez, J., Vanbelle, C., Morel, A. P., Gillet, G., Mikaelian, I., and Rimokh, R. (2011) Antagonistic regulation of EMT by TIF1 $\gamma$  and Smad4 in mammary epithelial cells. *EMBO Rep.* **12,** 665–672
- 37. He, W., Dorn, D. C., Erdjument-Bromage, H., Tempst, P., Moore, M. A., and Massagué, J. (2006) Hematopoiesis controlled by distinct TIF1 $\gamma$  and Smad4 branches of the TGFB pathway. *Cell* 125, 929-941
- 38. Xi, Q., Wang, Z., Zaromytidou, A. I., Zhang, X. H., Chow-Tsang, L. F., Liu, J. X., Kim, H., Barlas, A., Manova-Todorova, K., Kaartinen, V., Studer, L., Mark, W., Patel, D. J., and Massagué, J. (2011) A poised chromatin platform for TGF- access to master regulators. *Cell* **147,** 1511–1524
- 39. Peng, H., Feldman, I., and Rauscher, F. J., 3rd. (2002) Hetero-oligomerization among the TIF family of RBCC/TRIM domain-containing nuclear cofactors: a potential mechanism for regulating the switch between coactivation and corepression. *J. Mol. Biol.* **320,** 629–644
- 40. Dupont, S., Zacchigna, L., Cordenonsi, M., Soligo, S., Adorno, M., Rugge, M., and Piccolo, S. (2005) Germ-layer specification and control of cell growth by Ectodermin, a Smad4 ubiquitin ligase. *Cell* **121,** 87–99
- 41. Liang, Q., Deng, H., Li, X., Wu, X., Tang, Q., Chang, T. H., Peng, H., Rauscher, F. J., 3rd, Ozato, K., and Zhu, F. (2011) Tripartite motif-containing protein 28 is a small ubiquitin-related modifier E3 ligase and negative regulator of IFN regulatory factor 7. *J. Immunol.* **187,** 4754–4763
- 42. Xu, J., Lamouille, S., and Derynck, R. (2009) TGF- $\beta$ -induced epithelial to mesenchymal transition. *Cell Res.* **19,** 156–172
- 43. Gordon, G. M., Ledee, D. R., Feuer, W. J., and Fini, M. E. (2009) Cytokines and signaling pathways regulating matrix metalloproteinase-9 (MMP-9) expression in corneal epithelial cells. *J. Cell Physiol.* **221,** 402–411
- 44. Gerwin, B. I., Keski-Oja, J., Seddon, M., Lechner, J. F., and Harris, C. C. (1990) TGF- $\beta$  1 modulation of urokinase and PAI-1 expression in human bronchial epithelial cells. *Am. J. Physiol.* **259,** L262–L269
- 45. Chaudhury, A., and Howe, P. H. (2009) The tale of transforming growth factor- (TGF) signaling: a soigné enigma. *IUBMB Life* **61,** 929–939
- 46. Pot, I., Ikeuchi, Y., Bonni, A., and Bonni, S. (2010) SnoN: bridging neurobiology and cancer biology. *Curr. Mol. Med.* **10,** 667–673